Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

77P - Identification of prognostic and predictive immunological biomarkers in stage I and III non-small cell lung cancer (NSCLC) patients: A prospective exploratory study

Date

16 Sep 2021

Session

ePoster Display

Topics

Radiation Oncology

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Rianne Vaes

Citation

Annals of Oncology (2021) 32 (suppl_5): S382-S406. 10.1016/annonc/annonc686

Authors

R. Vaes1, K. Reynders2, J. Sprooten3, K. Nevola4, A. Garg3, M. Lambrecht5, L.E.L. Hendriks6, M. Rucevic4, D. De Ruysscher1

Author affiliations

  • 1 Department Of Radiation Oncology (maastro), GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, 6229 ET - Maastricht/NL
  • 2 Department Of Radiation Oncology (maastro), GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht/NL
  • 3 Cell Stress & Immunity (csi) Lab, Department For Cellular And Molecular Medicine, KU Leuven, Leuven/BE
  • 4 Olink Proteomics, OLINK Proteomics, Uppsala/SE
  • 5 Department Of Radiotherapy-oncology, Leuven Kanker Instituut, Universitair Ziekenhuis (UZ) Gasthuisberg, Leuven/BE
  • 6 Department Of Pulmonary Diseases, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, 6202 AZ - Maastricht/NL

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 77P

Background

Radiotherapy (RT) and chemotherapy can induce immune responses, but not much is known regarding treatment-induced immune changes in patients. The aim of this exploratory study was to identify immune signatures that are associated with progression free survival (PFS).

Methods

In a prospective study, (NCT02921854) patients with stage I (n=26) and stage III (n=18) NSCLC were included. Stage I patients were treated with stereotactic body radiation therapy (SBRT) and stage III patients with concurrent chemoradiotherapy (CCRT; cisplatin/etoposide, 60-66 Gy). Blood samples were collected before, during, and after RT and were screened by plasma proteomic analysis for >1000 proteins using Proximity Extension Assay (Olink Proteomics). Data were analyzed using the cox-proportional hazards model and Benjamini and Hochberg multiple hypothesis correction. A functional assay was used to assess the peripheral immuno-modulatory activity (e.g. IFN response).

Results

In stage I NSCLC, CD244 was identified as a potential prognostic biomarker (HR:10.2, 95%CI: 1.8-57.4). Patients with increased expression levels of CD244 before the start of RT have a lower PFS compared to those with lower CD244 levels (19.1 vs 27.2 months). Potential predictive biomarkers that have been identified include IL-10 (HR:11.8, 95%CI: 2.4-58.1) and Oncostatin M (HR:3.2, 95%CI:1.5-7.1). However, the circulating levels of all identified proteins were not affected by RT as the observed differences were already present at baseline. Furthermore, PFS was not associated with activation of peripheral IFN response. In patients with stage III NSCLC, no potential predictive and prognostic biomarkers were identified despite the dynamic expression of immune proteins during RT.

Conclusions

In this exploratory study, we observed that baseline expression of several immunogenic proteins might be a determining factor in predicting PFS in stage I NSCLC, treated with SBRT. For CCRT patients, the immunosuppressive effects of chemotherapy may nullify any relevant RT-induced immune changes. This study forms the basis for additional studies concerning immunological biomarkers.

Clinical trial identification

NCT02921854.

Editorial acknowledgement

Legal entity responsible for the study

Maastro.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.